Healthcare -
Biotechnology - NASDAQ - US
$ 12.4
-8.35 %
$ 779 M
Market Cap
-3.39
P/E
1. INTRINSIC VALUE
Balance Sheet
Mineralys Therapeutics, Inc.
| Current Assets | 205 M |
| Cash & Short-Term Investments | 198 M |
| Receivables | 0 |
| Other Current Assets | 7.16 M |
| Non-Current Assets | 552 K |
| Long-Term Investments | 0 |
| PP&E | 53 K |
| Other Non-Current Assets | 499 K |
| Current Liabilities | 14.6 M |
| Accounts Payable | 479 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 14.2 M |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Mineralys Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 192 M |
| Operating Income | -192 M |
| Other Expenses | -14.6 M |
| Net Income | -178 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Mineralys Therapeutics, Inc.
| Net Income | -178 M |
| Depreciation & Amortization | 43 K |
| Capital Expenditures | -96 K |
| Stock-Based Compensation | 11.3 M |
| Change in Working Capital | 9.52 M |
| Others | -307 K |
| Free Cash Flow | -166 M |
Wall Street Analysts Price Targets
Mineralys Therapeutics, Inc.
MLYS has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
MLYS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Mineralys Therapeutics, Inc.
Sold
0-3 MONTHS
264 K USD 2
3-6 MONTHS
811 K USD 3
6-9 MONTHS
7.54 M USD 4
9-12 MONTHS
2.77 M USD 3
Bought
33.7 M USD 3
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
RADNOR, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the closing of the sale of an additional 1,944,444 shares of its common stock at a public offering price of $13.50 per share pursuant to the exercise in full of the underwriters' option to purchase additional shares in connection with Mineralys' recently completed public offering. After giving effect to the sale of these additional shares, the aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $201.2 million. All of the securities sold in the offering were sold by Mineralys.
globenewswire.com
- 2 weeks ago
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo
RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that data from the Phase 2 Advance-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) will be presented in a late-breaking clinical trials session at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25), which is being held in Chicago on March 29-31, 2025.
globenewswire.com
- 3 weeks ago
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Wednesday.
benzinga.com
- 3 weeks ago
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
RADNOR, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an underwritten public offering of 12,962,962 shares of its common stock at a public offering price of $13.50 per share. The aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $175.0 million. In addition, Mineralys has granted the underwriters a 30-day option to purchase up to an additional 1,944,444 shares of its common stock. All of the securities to be sold in the offering are to be sold by Mineralys. The offering is expected to close on or about March 13, 2025, subject to the satisfaction of customary closing conditions.
globenewswire.com
- 3 weeks ago
Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts
Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met with statistical significance. Upcoming catalysts include the full data release from Advance-HTN in March 2025 and phase 2 Explore-CKD trial results in Q2 2025. Financially, company has $198.2 million in cash but may need to raise funds soon, potentially diluting shareholders.
seekingalpha.com
- 3 weeks ago
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. In addition, Mineralys expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the securities to be sold in the offering are to be sold by Mineralys. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
globenewswire.com
- 3 weeks ago
Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate
On Monday, Mineralys Therapeutics, Inc. MLYS released topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials of lorundrostat for uncontrolled hypertension (uHTN) or resistant hypertension (rHTN).
benzinga.com
- 3 weeks ago
Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 700 points on Monday.
benzinga.com
- 3 weeks ago
Mineralys Therapeutics' blood pressure drug meets goal in trials
Mineralys Therapeutics said on Monday its blood pressure drug, lorundrostat, met the main goal in late- and mid- stage trials.
reuters.com
- 4 weeks ago
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
– Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by automated office blood pressure at week 6 – – Launch-HTN met a predefined endpoint with lorundrostat 50 mg dose achieving a 19.0 mmHg reduction in systolic blood pressure, and an 11.7 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by automated office blood pressure at end of treatment, week 12 – – Advance-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a highly statistically significant 7.9 mmHg placebo-adjusted reduction assessed by 24hr ABPM at end of treatment, week 12 – – Lorundrostat demonstrated a favorable safety and tolerability profile in both pivotal trials – – Full results from Advance-HTN to be presented on March 29, 2025, at the American College of Cardiology Scientific Sessions – – Conference call today at 8:00 a.m. ET – RADNOR, Pa.
globenewswire.com
- 4 weeks ago
Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
RADNOR, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar to announce topline results from its Launch-HTN and Advance-HTN pivotal trials on Monday, March 10, 2025, at 8:00 a.m. ET.
globenewswire.com
- 1 month ago
Mineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call Transcript
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q4 2024 Results Conference Call February 12, 2025 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore ISI Rich Law - Goldman Sachs Annabel Samimy - Stifel Mohit Bansal - Wells Fargo Rami Khadkar - LifeSci Capital Matthew Caufield - H. C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the Mineralys Fourth Quarter and Full Year 2024 Earnings Conference Call.
seekingalpha.com
- 1 month ago
8. Profile
Summary
Mineralys Therapeutics, Inc. MLYS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 779 M
Dividend Yield
0.00%
Description
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Contact
150 N. Radnor Chester Rd., Radnor, PA, 19087
https://mineralystx.com
IPO
Date
Feb. 10, 2023
Employees
51
Officers
Mr. Adam Scott Levy
Chief Financial Officer & Secretary
Ms. Jessica Ibbitson
Senior Vice President of Clinical Operations
Ms. Cindy Berejikian
Executive Vice President of Operations
Mr. Jeffrey N. Fellows
Senior Vice President of Regulatory Affairs
Dr. Robert McKean Ph.D.
Senior Vice President of CMC
Dr. David M. Rodman M.D.
Chief Medical Officer
Ms. Sarah Foster
Vice President of Human Resources
Mr. Jon Congleton
Chief Executive Officer & Director
Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D.
Founder & Executive Director
Ms. Danielle Bradbury
Senior Vice President of Quality Assurance